SPY415.87+4.42 1.07%
DIA340.44+2.91 0.86%
IXIC14,038.76+180.92 1.31%

BRIEF-Tonix Pharma Says Data Shows TNX-1800 Induces Protection Against SARS-COV-2 Infection In Non-Human Primates

· 03/17/2021 07:00
BRIEF-Tonix Pharma Says Data Shows TNX-1800 Induces Protection Against SARS-COV-2 Infection In Non-Human Primates

- TONIX PHARMACEUTICALS :

  • TONIX PHARMA REPORTS POSITIVE COVID-19 VACCINE EFFICACY RESULTS IN NON-HUMAN PRIMATES VACCINATED WITH TNX-1800 & CHALLENGED WITH LIVE SARS-COV-2

  • TONIX PHARMACEUTICALS - TNX-1800 PHASE 1 HUMAN STUDY TARGETED TO START IN H2 2021, FOLLOWING IND CLEARANCE BY FDA & PRODUCTION OF GMP MATERIAL

  • TONIX PHARMA - ALL 8 ANIMALS VACCINATED WITH TNX-1800 HAD UNDETECTABLE SARS-COV-2 IN UPPER & LOWER AIRWAYS 6 DAYS AFTER CHALLENGE WITH SARS-COV-2

  • TONIX PHARMACEUTICALS - TNX-1800 WILL BE GLASS-SPARING, WITH 100 DOSES FILLED PER VIAL

  • TONIX PHARMACEUTICALS - TNX-1800 AND TNX-801 WERE WELL TOLERATED AT BOTH DOSES IN STUDY

  • TONIX PHARMACEUTICALS - DATA SHOWS THAT TNX-1800 INDUCES PROTECTION AGAINST SARS-COV-2 INFECTION IN NON-HUMAN PRIMATES

Source text for Eikon: ID:nGNX8Z6CFf

Further company coverage: TNXP.O


((Reuters.Briefs@thomsonreuters.com;))